PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Org Lett. Author manuscript; available in PMC 2010 September 3.
Published in final edited form as:
PMCID: PMC2838230
NIHMSID: NIHMS135809

Total Synthesis of Brevisamide

Abstract

An external file that holds a picture, illustration, etc.
Object name is nihms135809u1.jpg

The second total synthesis of Brevisamide, a marine cyclic ether alkaloid from Karenia brevis is reported. This streamlined synthesis proceeds in 21 steps, 14 steps longest linear sequence, in 5.2% overall yield and features a key SmI2 reductive cyclization step to access the tetrasubstituted pyran core.

Recently, Satake, Tachibana, Wright and co-workers reported on the isolation and characterization of brevisamide (1), an unprecendented monocylic ether alkaloid, from the dinoflagellate Karenia brevis, a species known to produce polycyclic ether toxins such as the brevetoxins.1 Identification of 1, containing the same conjugated 3,4-dimethyl-2,4-dienal side chain as the more complex polycylic ether brevenal,2 provided further support for the model of ladder-frame initiation in the synthesis of polycyclic ether natural products, and thus has garnered significant synthetic interest.1 Within months of the publication of the isolation and characterization of brevisamide (1), the first total synthesis and structural confirmation of 1 was reported by the same group.3 The synthesis proceeded in 28 steps, with the longest linear sequence of 21 steps, for an overall yield of 1 from cis-but-2-ene diol of 0.23%.3 In this letter, we wish to report our efforts on the total synthesis of brevisamide (1) employing a fundamentally different synthetic strategy that afforded 1 in 21 total synthetic steps and an overall yield of 5.2%.

Scheme 1 illustrates our retrosynthetic analysis of 1, providing a convergent synthetic strategy. Inspired by the elegant synthesis of brevenal by Takamura and coworkers,4 we envisioned the western C1-C4 side chain would be installed through a Horner-Emmons-Wadsworth reaction utilizing 2, prepared from commercially available 4. Key pyran 3, the C5-C15 fragment, was conceived to be derived from 5 through a SmI2-mediated reductive cyclization reaction.5-10

Scheme 1
Retrosynthetic analysis of brevisamide (1)

The synthesis of pyran 3 is described in Scheme 2. Mono-benzyl protected-1,4-butane diol 6 was oxidized under Swern conditions to the corresponding aldehyde which was then subjected to a Brown crotylation reaction to afford 7 as a single diastereomer in 87% ee.11,12 Hydroboration and chemoselective TBS protection of the primary alcohol provided 8 in 89% yield for the two steps. 1,4-addition of 8 to ethyl propiolate proved difficult, resulting in complex mixtures under a number of reaction conditions.13 Ultimately, slow addition of ethyl propiolate via syringe pump over 24 hours delivered the key intermediate 9 in 93% isolated yield. Removal of the TBS group proved equally problematic. Upon exposure to TBAF, a 1:1 mixture of the desired 10 and an unanticipated 1,3-dioxepane 11 formed. While separable, this undesired side product was detrimental at this stage of the synthesis. After surveying a variety of reaction conditions, we found that addition of a few drops of concentrated HCl in MeOH at 0 °C smoothly delivered the alcohol 10 in quantitative yield. Swern oxidation proceeded uneventfully delivering the key template for the reductive cyclization.5-10 In the event, exposure to SmI2 provided the desired pyran 12 in 69% yield for the three steps. The relative stereochemistry of 12 was assigned by NMR and nOe analysis, and in agreement with literature precedent.5-10

Scheme 2
Synthesis of tetra-substituted pyran 3.

Once in hand, the secondary alcohol of 12 was protected and the ester hydrolyzed to produce acid 13 in 85% yield for the two steps. Curtius rearragement with (PhO)2P(O)N3 (DPPA) provided the aminomethyl congener 14 in 81% yield.14,15 Finally, an acetylation, benzyl deprotection and oxidation sequence afforded target pyran 3, the C5-C15 fragment, in 81% yield for the three steps. Thus, the longest linear sequence, 13 steps, was completed in 14.9% overall yield.

Attention now focused on the synthesis of phosphonate ester 2.4 As shown in Scheme 3, a Wittig reaction with 3-hydroxybutan-2-one 4, and subsequent bromination, generates the secondary bromide 15 in 90% yield for the two steps. Application of an Arbuzov reaction delivers the key phosphoate ester 2, the C1-C4 side chain, in 92% yield.4,16

Scheme 3
Synthesis of phosphonate ester 2

The Horner-Wadsworth-Emmons reaction between the C1-C4 fragment 2 and the C5-C15 fragment 3 proceeded well, installing the conjugated 3,4-dimethyl-2,4-dienal moiety and delivering 16 in 78% yield (Scheme 4). DIBALH reduction of the ester to the corresponding allylic alcohol4 and TBAF-mediated deprotection of the secondary TBS ether delivered 17, the direct precursor to brevisamide, in 71% yield for the two steps. A final MnO2 oxidation of the allylic alcohol produced the natural product brevisamide (1) in 74% yield. The synthetic 1 exhibited physical and spectroscopic data identical to that of the natural brevisamide and that of the previously prepared synthetic brevisamide.1,3,17

Scheme 4
Completion of the synthesis of brevisamide (1).

Thus, the second total synthesis of brevisamide (1) has been accomplished in 21 synthetic steps, with 14 steps longest linear sequence, and an overall yield from mono-benzyl protected-1,4-butane diol 6 of 5.2%. Noteworthy synthetic steps from this route include a SmI2 reductive cyclization to generate the highly functionalized pyran 3 and a Horner-Wadsworth-Emmons reaction to assemble the western C1-C4 2 and eastern C5-C15 3 fragments. With a high-yielding synthetic route in place, future efforts will focus on the synthesis of unnatural brevisamide analogs and attempts to employ 1 in the biomimetic, ladder-frame initiated synthesis of more complex polyethers. These efforts are in progress and will be reported in due course.

Supplementary Material

1_si_001

Acknowledgments

This work was supported, in part, by the Department of Pharamacology and Vanderbilt University. Funding for the NMR instrumentation was provided in part by a grant from NIH (S10 RR019022). The authors thank Dr. Kyle Emmitte (Vanderbilt University) for helpful conversations.

Footnotes

Supporting Information Available: Experimental procedures, characterization data, and 1H and 13C NMR spectra for all new compounds. This material is avaialble free of charge via the internet at http://pubs.acs.org.

References

1. Satake M, Bourdelais AJ, Van Wagoner RM, Baden DG, Wright JLC. Org Lett. 2008;10:3465–3468. [PMC free article] [PubMed]
2. Bourdelais AJ, Jacocks HM, Wright JLC, Bigwarfe PM, Jr, Baden DGJ. Nat Prod. 2005;68:2–6. [PMC free article] [PubMed]
3. Kuranaga T, Shirai T, Baden DG, Wright JLC, Satake M, Tachibana K. Org Lett. 2009;11:217–220. [PubMed]
4. Takamura H, Kikuchi S, Nakamura Y, Yamagami Y, Kishi T, Kadota I, Yamamoto Y. Org Lett. 2009;11:2531–2534. [PubMed]
5. Gillmann T. Tetrahedron Lett. 1993;34:607–610.
6. Suzuki K, Matsukura H, Matsuo G, Koshino H, Nakata T. Tetrahderon Lett. 2002;43:8653–8655.
7. McErlean CSP, Willis AC. Synlett. 2009;2:233–236.
8. Clark SJ, Hayes ST, Blake AJ, Gobbi L. Tetrahedron Lett. 2007;48:2501–2503.
9. Saito T, Kimishima A, Nakata T. Heterocycles. 2006;70:177–180.
10. Takahashi S, Ogawa N, Koshino H, Nakata T. Org Lett. 2005;7:2783–2786. [PubMed]
11. Racherla US, Brown HC. J Org Chem. 1991;56:401–404.
12. Williams DR, Cortez GS, Bogen SL, Rojas CM. Angew Chem Int Ed. 2000;39:4612–4617. [PubMed]
13. Kartika R, Gruffi TR, Taylor RE. Org Lett. 2008;10:5047–5050. [PubMed]
14. Davis MC. Synth Commun. 2007;37:3519–3528.
15. Leogane O, Lebel H. SYNTHESIS. 2009;11:1935–1940.
16. Alen J, Dobrzanska L, De Morggraeve WM, Compernolle F. J Org Chem. 2007;72:1055–1057. [PubMed]
17. See Supporting Information for full details.